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This article presents the incidence of ciproﬂoxacin resistance among 480 clinical isolates obtained from patients with urinary tract
infection (UTI) during January to June 2004 in Gaza Strip, Palestine. The resistance rates observed were 15.0% to ciproﬂoxacin,
82.5% to amoxycillin, 64.4% to cotrimoxazole, 63.1% to doxycycline, 32.5% to cephalexin, 31.9% to nalidixic acid, and 10.0% to
amikacin. High resistance to ciproﬂoxacin was detected among Acinetobacter haemolyticus (28.6%), Staphylococcus saprophyticus
(25.0%), Pseudomonas aeruginosa (20.0%), Klebsiella pneumonia (17.6%), and Escherichia coli (12.0%). Minimal inhibitory con-
centration (MIC) of ciproﬂoxacin evenly ranged from 4 to 32µg/mL with a mean of 25.0µg/mL. This study indicates emerging
ciproﬂoxacin resistance among urinary tract infection isolates. Increasing resistance against ciproﬂoxacin demands coordinated
monitoring of its activity and rational use of the antibiotics.
INTRODUCTION
Urinary tract infections (UTIs) are the second most
common infections in community practice. Worldwide,
about 150 million people are diagnosed with UTI each
year costing the global economy in excess of 6 billion US
dollars [1].
All over the world, Escherichia coli accounts for 75%
to 90% of UTI isolates and Staphylococcus saprophyticus
accounts for 5% to 15% of cases of uncomplicated cystitis
[2].
Antibiotics used in the therapy of UTI are usually able
to reach high urinary concentrations, which are likely to
be clinically eﬀective. Fluoroquinolones are preferred as
initial agents for empiric therapy of UTI in areas where
resistance is likely to be of concern [3, 4]. This is be-
causetheyhaveahighbacteriologicandclinicalcurerates,
as well as low rates of resistance, among most common
uropathogens [4].
Ciproﬂoxacin is the most frequently prescribed ﬂuo-
roquinoloneforUTIsbecauseofitsavailabilityinoraland
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intravenous formulations. Ciproﬂoxacin has shown an
excellent activity against pathogens commonly encoun-
tered in complicated UTIs. It is well absorbed from oral
doses and is rapidly excreted from the body under normal
conditions [3, 5, 6].
Resistance to ﬂuoroquinolones has increased
markedly since their introduction for UTI treatment.
Many studies worldwide reported a clear increase in
ciproﬂoxacin resistance. For instance, in China, from
1998 to 2002 the incidence of ciproﬂoxacin resistance
increased steadily from 46.6% to 59.4% [7]. In Spain,
it was 14.7% [8], and in Bangladesh, it was 26.0% [9].
However, in previous studies in Gaza Strip, the resistance
to ciproﬂoxacin among all isolates in 2000 was 4.1% and
among Ec o l iwas only 2.9% [10] whereas, it increased to
11.3% in 2002 [11].
Evolving changes in drug resistance in various com-
munities have forced the importance to a reassessment
of local empiric choices for managing UTI [8, 12]. The
present study describes the most common organisms
causing UTI in Gaza Strip and evaluates the antibacte-
rial activity of ciproﬂoxacin against recently isolated UTI
pathogens.
METHODOLOGY
Samplecollectionandprocessing
A total of 1278 clean voided midstream urine sam-
ples were collected from the main three Gaza Strip gov-
ernmental hospitals (Al Shefaa, Khan Younis, and the2005:3 (2005) Increasing Ciproﬂoxacin Resistance in Gaza Strip 239
Gaza European hospital) from UTI adult outpatients (the
physician suspected infection) aged 18–60 years during
January to June 2004. The study was carried out at Khan
Younis Hospital Laboratory, Palestine.
One sample per patient was collected consecutively
from each of the 1278 UTI suspected cases (831 female
and 447 male) to avoid strain duplication. Samples were
stored at 2−−4◦C until being processed on the same day.
Positive culture was deﬁned as the culture of a single mi-
croorganism at a concentration of ≥ 105 CFU/mL [13].
The nature of the work followed in the present study
was fully explained to all subjects, and the study was con-
ducted with their informed consent.
Each specimen was inoculated on both blood agar
(with 5% deﬁbrinated sheep blood) and MacConkey agar
plates using a 0.01mL standard loop (for semiquantita-
tive counts) and incubated aerobically at 37◦C for 24–48
hours and the number of colonies was counted. Signif-
icant growth was identiﬁed biochemically and serologi-
cally in a systematic way according to standard methods
[14]. All Gram-negative rods were identiﬁed by using API
20Estrips.Staphylococciwereidentiﬁedbycatalase,coag-
ulase, novobiocin, DNase, and Staphylococcus latex tests.
The initial characterization of enterococci was based on
catalasereaction,hemolysis,andcolonymorphology.Fur-
theridentiﬁcationofenterococciwasaccomplishedbythe
useofbileesculintest.Enterococciwerealsoconﬁrmedby
a serologic procedure “strep-check test” (Lorne Laborato-
ries Ltd, Twyford, UK).
Antimicrobialsusceptibilitytesting
Antimicrobial susceptibility testing of the bacterial
isolates was performed by the disk diﬀusion method [15]
in accordance with the National Committee for Clinical
Laboratory Standards (NCCLS) [16].
Quality controls employed standard strains of Ec o l i
ATCC 25922, Pseudomonas aeruginosa ATCC 27853, and
Enterococcus faecalis 29212. Interpretive criteria for sus-
ceptibility or resistance followed NCCLS guidelines [16].
For this report, we present susceptibility data for amoxy-
cillin, 25µg; cephalexin, 30µg; cefuroxime, 30µg; cef-
tazidime, 30µg; cotrimoxazole, 1.25–23.75µg; nalidixic
acid, 30µg; ciproﬂoxacin, 5µg; doxycycline, 30IU; nitro-
furantoin,300µg;gentamycin,10µg;andamikacin,30µg.
The ciproﬂoxacin minimum inhibitory concentration
(MIC) was conﬁrmed by E-test strips (AB Biodisk, Solna,
Sweden). The ciproﬂoxacin MIC (µg/mL) used to deﬁne
resistant isolates was ≥ 4, as outlined by the National
Committee for Clinical Laboratory Standards [16].
Statisticalanalysis
Statistical analysis was performed by the chi-square
test and P values of ≤ 0.05 were considered signiﬁcant.
RESULTS
Of the 1278 urine samples processed, 492 (38.5%)
showed positive monomicrobial cultures. Gram-negative
Table 1.Frequencyofmicroorganismsisolatedfrom480outpa-
tients positive urine cultures. Figures reﬂect the number of the
isolates.
Microorganisms Frequency %
Escherichia coli 252 52.5
Proteus mirabilis 47 9.8
Klebsiella pneumonia 44 9.2
Pseudomonas aeruginosa 43 9.0
Enterobacter cloacae 33 6.9
Acinetobacter haemolyticus 18 3.8
Enterococcus faecalis 25 5.2
Staphylococcus saprophyticus 18 3.8
Total 480 100.0
bacteria represented 437 (91.0%) of the positive bacterial
cultures (480), whereas Gram-positive were 43 (9.0%).
Twelve isolates (2.5% of 492) of yeast were encoun-
tered during the screening of UTI specimens. The yeast
isolates were not included in this analysis because our
study is concerned only with bacterial uropathogens and
their antimicrobial susceptibility.
The overall sex distribution of the subjects was 831
(65.0%) females and 447 (35.0%) males and the sex dis-
tribution for the 480 positive cultures was 360 (75.0%)
females and 120 (25.0%) males with a statistical signiﬁ-
cance (P = .03) predominance of females with UTI. The
patients mean age was 31.6 ±10.3y e a r s .
A summary of the diﬀerent microorganisms isolated
during the study period is shown in Table 1. It is clear that
Ec o l iwas the predominant uropathogen (52.5%) caus-
ing UTI followed by Proteus mirabilis (9.8%) and Kleb-
siella pneumonia (9.2%) whereas E faecalis was the most
common uropathogen (5.2%) isolated among the Gram-
positive bacteria.
High rates of resistance were found to amoxy-
cillin (82.5%), followed by cotrimoxazole (64.4%) and
doxycycline (63.1%) while the lowest resistance was to
amikacin and ceftazidime (10.0%). The resistance rate to
ciproﬂoxacin was 15.0%. The MICs for ciproﬂoxacin re-
sistant isolates evenly ranged from 4 to 32µg/mL with a
mean of 25.0µg/mL.
The isolated bacteria showed wide diﬀerences in
their susceptibility to the tested antimicrobial drugs. A
high resistance rate to ciproﬂoxacin was observed among
the Acinetobacter haemolyticus (28.6%), Ss a p r o p h y t i c u s
(25.0%), and Pa e r u g i n o s a(20.0%) whereas E faecalis was
the lowest resistant one (9.1%). The resistance to nitrofu-
rantoin was only 2.7% among Ec o l iand 28.6% among
Ah a e m o l y t i c u s . On the other hand, the resistance to
nalidixic acid was 16.0% among Ec o l iand 57.1% among
Ah a e m o l y t i c u s .
DISCUSSION
The importance of this study lies in describing the
most common bacteria causing UTI among outpatients240 Zakaria El Astal 2005:3 (2005)
Table 2. Antimicrobial resistance percentage of 480 clinical bacterial strains isolated from urinary tract infections. AMX, amoxycillin;
CF, cephalexin; CTX, cefuroxime; CTZ, ceftazidime; GM, gentamycin; AN, amikacin; SXT, cotrimoxazole; DOX, doxycycline; NA,
nalidixic acid; CIP, ciproﬂoxacin; and NF, nitrofurantoin.
Isolates
Antimicrobial agent
AMX GM AN SXT DOX CF CTX CTZ NA CIP NF
%%%%%%%%%%%
Escherichia coli 78.7 14.7 2.7 58.7 58.7 18.7 10.7 4.0 16.0 12.0 2.7
Proteus mirabilis 84.2 36.8 10.5 68.4 63.2 47.4 21.1 15.8 31.6 15.8 89.5
Klebsiella pneumonia 88.2 11.8 11.8 76.5 76.5 23.5 11.8 11.8 23.5 17.6 5.9
Pseudomonas aeruginosa 93.3 33.3 13.3 66.7 73.3 60.0 53.3 13.3 56.7 20.0 100.0
Enterobacter cloacae 83.3 41.7 8.3 66.7 66.7 50.0 25.0 16.7 25.0 16.7 8.3
Acinetobacter haemolyticus 85.7 57.1 14.3 71.4 71.4 71.4 42.9 14.3 57.1 28.6 28.6
Enterococcus faecalis 81.8 45.5 36.4 63.6 45.5 NT NT NT 100.0 9.1 27.3
Staphylococcus saprophyticus 75.0 50.0 50.0 75.0 75.0 25.0 25.0 25.0 100.0 25.0 25.0
Resistance mean 82.5 25.6 10.0 64.4 63.1 32.5 19.4 10.0 31.9 15.0 26.3
P value 0.917 0.018 0.005 0.911 0.708 0.004 0.011 0.482 0.000 0.921 0.000
in Gaza Strip and their resistance to 11 selected antimi-
crobial agents.
The sex distribution of patients in the present study is
consistent with that of other studies [17, 18]. The signif-
icant diﬀerences in UTI rates between females and males
are thought to be due to anatomical diﬀerences between
thesexes.Amongotherfactors,thelengthoftheurethra,a
drier environment surrounding the meatus, and antibac-
terial properties of prostatic ﬂuid contribute to a lower
rate of infection in males [19].
In this study, the predominance of Ec o l iamong
Gram-negative bacteria followed by P mirabilis, Kp n e u -
monia, and, among Gram-positive bacteria, E faecalis
(Table 1), was similar to many authors results all over the
world [20, 21, 22, 23].
The prevalence of Ec o l imay be due to its existence
as a normal ﬂora in the large intestine and female vagina.
The possible source of E faecalis infection could be due
to a previous catheterization and those patients may be
considered “complicated UTI” cases.
Notably, comparison among diﬀerent studies con-
cerningresistanceofuropathogenstodiﬀerentantimicro-
bial agents should take into account the diﬀerent periods
i nw h i c hs u c hs t u d i e sw e r ec a r r i e do u ta sw e l la sv a r i -
ous socioeconomical, socioepidemiological, and clinical
parameters of the target population. Moreover, the com-
parison must consider the limitation of resistance to an-
timicrobials, which can vary from country to another.
The resistance of antimicrobial agents tested showed
high resistance rates to amoxycillin, cotrimoxazole, and
doxycycline while the lowest resistance was to amikacin
and ceftazidime. The resistance rate of ciproﬂoxacin was
15.0% whereas, in a previous study (2000) carried out in
Gaza Strip, lower resistance to ciproﬂoxacin (4.1%) was
reported [10]. The widespread and more often the misuse
of antimicrobial drugs in Gaza Strip have led to a general
rise in the emergence of resistant bacteria, particularly to
ciproﬂoxacin.
Higher resistance was reported in the USA to ampi-
cillin and cotrimoxazole [24] whereas, for ciproﬂoxacin
resistance, lower rates were found in other countries [25,
26].
Among Gram-negative bacteria, Ec o l i , Kp n e u m o n i a ,
and Enterobactercloacaewere more susceptible to nitrofu-
rantoin (Table 2). These data suggest that nitrofurantoin
may still be useful for the treatment of UTIs, especially for
the mentioned organisms.
When comparing the high resistance rates in this
study to ciproﬂoxacin against Acinetobacter haemolyti-
cus, Ss a p r o p h y t i c u s , Pa e r u g i n o s a , Ec o l i ,a n dE faecalis
with other authors, higher resistance rates were reported
[7, 8].
There are many reasons for this alarming phe-
nomenon, including inappropriate prescribing of antibi-
otics and poor infection control strategies [27]. The sit-
uation in Gaza Strip, in terms of antimicrobial drug use,
is not so diﬀerent from that of many developing coun-
tries, where people usually take antimicrobial drugs with-
outprescription orwithoutperformingthe necessarycul-
ture testing.
The considerably high MIC values for ciproﬂoxacin
reﬂects the extent of treatment problem for resistant iso-
lates.
Overall susceptibility testing of this study demon-
strates increased resistance to many commonly used
agents especially to ciproﬂoxacin and illustrates the need
for a continuous evaluation for the common antibiotics
used in the therapy of uropathogens.
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